Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Petrovič D, Milanez T, Kobal J, Bregar D, Potisk KP, Peterlin B. Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction.

Acta Neurol Scand 2003: 108: 109–113. © Blackwell Munksgaard 2003. Objectives –

To test the hypothesis whether risk genotypes of the prothrombotic gene polymorphisms (I/D 4G5G PAI-1, G1691A factor V point mutation, factor VII Arg/Gln353) are risk factors for ACI in the Slovene population. The study sought an association between the insertion/deletion 4G/5G-plasminogen activator inhibitor 1 (PAI-1) gene polymorphism, the 1691G-A factor V point mutation or the arg353-to-gln factor VII gene polymorphism and atherothrombotic cerebral infarction (ACI). Material and methods –

Ninety-six Slovene patients who suffered ACI were compared with 115 control subjects clinically free of cerebrovascular disease. Insertion/deletion 4G/5G PAI-1 gene polymorphism, 1691G-A factor V point mutation and arg353-to-gln polymorphism in the factor VII were determined using polymerase chain reaction. Results –

The 4G4G genotype of 4G5G PAI-1 gene polymorphism was less frequent in cases (21.9%) than in controls (35.6%; OR = 0.5, 95% CI = 0.3–1; P = 0.033). No association was found either between the factor V point mutation (1691G-A) or the RR genotype of the factor VII Arg/Gln353 gene polymorphism and the risk of ACI using univariate analysis. Conclusion –

The 4G/4G-PAI-1 genotype might be a protective factor against ACI, whereas the factor V point mutation (1691G-A) and the factor VII Arg/Gln353 gene polymorphism have not proved to be risk factors for ACI.

Keywords: 4G/5G PAI-1 gene promoter polymorphism; G1691A factor V point mutation; atherothrombotic stroke; factor VII Arg/Gln353 gene polymorphism; risk factors

Document Type: Research Article

DOI: http://dx.doi.org/10.1034/j.1600-0404.2003.00126.x

Affiliations: 1: Institute of Histology and Embryology, Medical Faculty Ljubljana, Ljubljana; 2: Department of Nuclear Medicine, Medical Centre Ljubljana, Ljubljana; 3: Department of Neurology, Medical Centre Ljubljana, Ljubljana; 4: Institute for Rehabilitation Republic of Slovenia, Ljubljana; 5: Division of Medical Genetics, Department of Obstetrics and Gynaecology, Medical Centre Ljubljana, Slovenia

Publication date: August 1, 2003

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more